All-cause mortality in older adults with affective disorders and dementia under treatment with antipsychotic drugs: A matched-cohort study

Szmulewicz, Alejandro G.; Ferraris, Augusto; Rodriguez, Agustin A.; Cervera, Lucía Campos; González, Macarena López; Man, F. H. R. De; Angriman, Federico; Martino, Diego Javier

doi:10.1016/j.psychres.2018.04.034

Cited by 3 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No significant differences in death risk increase were found among atypical antipsychotics in a recent meta-analysis [ 177 ], however, quetiapine showed the lowest relative risk in a large retrospective cohort study [ 191 ]. Interestingly, the risk of all-cause mortality in older patients with mood disorders initiating antipsychotic treatment has been found to be similar to that of elderly with dementia, which means that increased mortality could be independent of diagnosis and solely related to antipsychotic treatment in older ages [ 192 ].…”

Section: Pharmacological and Physical Treatment Of (Hypo)manic Sympto...mentioning

confidence: 99%

Bipolar Disorder and Manic-Like Symptoms in Alzheimer’s, Vascular and Frontotemporal Dementia: A Systematic Review

Elefante

Brancati

Torrigiani

et al. 2023

View full text Add to dashboard Cite

Background: An increased risk of manic episodes has been reported in patients with neurodegenerative disorders, but the clinical features of bipolar disorder (BD) in different subtypes of dementia have not been thoroughly investigated. Objectives: The main aim of this study is systematically review clinical and therapeutic evidence about manic syndromes in patients with Alzheimer’s disease (AD), vascular dementia (VD), and frontotemporal dementia (FTD). Since manic-mixed episodes have been associated with negative outcomes in patients with dementia and often require medical intervention, we also critically summarized selected studies with relevance for the treatment of mania in patients with cognitive decline. Methods: A systematic review of the literature was conducted according to PRISMA guidelines. PubMed, Scopus and Web of Science databases were searched up to February 2022. Sixty-one articles on patients with AD, VaD or FTD and BD or (hypo)mania have been included. Results: Manic symptoms seem to be associated with disease progression in AD, have a greatly variable temporal relationship with cognitive decline in VaD, and frequently coincides with or precedes cognitive impairment in FTD. Overall, mood stabilizers and electroconvulsive therapy may be the most effective treatments, while the benefits of short-term treatment with antipsychotic agents must be balanced with the associated risks. Importantly, low-dose lithium salts may exert a neuroprotective activity in patients with AD. Conclusion: Prevalence, clinical features and treatment response to pharmacotherapy of manic syndromes in patients with dementia may be differentially affected by the nature of the underlying neurodegenerative conditions.

show abstract

Section: Pharmacological and Physical Treatment Of (Hypo)manic Sympto...mentioning

confidence: 99%